Craig joined OrganOx in December 2016, and took over the role of CEO from Dr Les Russell in January 2017.

Prior to joining OrganOx, Craig was Managing Director of the award-winning business Siemens Magnet Technology. During the period 2010—2016, he was also an executive member of the Siemens Healthcare MRI business, the undisputed market leader. During his time in these roles, Siemens Magnet Technology developed a revolutionary new magnet contained within the World's strongest clinical MRI system, the Siemens MRI 7 Tesla product, MAGNETOM Terra.

Craig is a fellow of the Institution of Mechanical Engineers, he holds a first degree from the University of Liverpool, and an MBA with Distinction from the acclaimed University of Warwick Business School.

Earlier in his career, he worked at Oxford Instruments, Amersham Plc and GE Healthcare in a variety of management and leadership roles, within the in vivo diagnostics sector.

Peter is OrganOx Co-Founder and Chief Medical Officer, and has worked with Constantin and the OrganOx team for more than 20 years on the development of OrganOx's normothermic organ perfusion technology. Peter leads OrganOx's pre-clinical and clinical programmes of OrganOx's patented normothermic organ perfusion technology.

Peter is Professor of Transplantation at the University of Oxford and Director of the Oxford Transplant Centre, where he is responsible for the kidney, small bowel and pancreatic transplant programmes. Earlier in his career Peter was Clinical Director of the Transplant Centre at Addenbrooke’s Hospital, Cambridge, one of the UK’s leading liver transplant centres and visiting Assistant Professor of Surgery at Indiana University Medical Centre, USA, where he established their liver transplant programme.

Peter's research interests lie primarily in novel applications of normothermic organ perfusion, ranging from its use for extracorporeal support to preservation and repair prior to transplantation. He has published over 25 papers on the topic of normothermic perfusion, the basis of the OrganOx technology, as well as in the areas of clinical transplantation, immunosuppression, monoclonal antibodies, xenotransplantation, liver perfusion and aspects of general surgery.

Constantin is OrganOx Co-Founder and Chief Technical Officer and has worked with Peter and the OrganOx team for more than 20 years on the development of OrganOx's normothermic organ perfusion technology. Constantin leads OrganOx's technical development programmes.

Constantin is Professor of Biomedical Engineering at the University of Oxford and Director of the Oxford Institute of Biomedical Engineering. Constantin founded and heads the Biomedical Ultrasonics, Biotherapy and Biopharmaceuticals Laboratory (BUBBL), he is also the Director of the Oxford Centre for Drug Delivery Devices (OxCD3).

Constantin's research interests include normothermic organ perfusion, drug delivery, acoustic cavitation and therapeutic ultrasound. Constantin received the 2017 Royal Academy of Engineering Silver Medal and was appointed as a Fellow of the Royal Academy of Engineering in 2019.

Graham joined OrganOx as Chief Financial Officer in June 2019. He has significant experience of being part of a senior leadership team for growth SMEs, implementing financial controls & procedures for managing significant change and growth, building capability and infrastructure, driving profitability, cash generation and value inflection. Graham has been in life sciences since 2006 and has undertaken two IPOs, numerous fundraisings (raising approx. £100m at hVIVO) and negotiated a number of complex licensing transactions and joint ventures.

Graham started his career with PricewaterhouseCoopers for 13 years, qualifying as a Chartered Accountant and working across its audit, tax, consultancy, business process re-engineering and outsourcing divisions. In 2001 he joined buyingTeam Limited (subsequently renamed Proxima) as Finance & Operations Director and was influential in growing the business to become one of the UK’s leading purchasing services providers. From 2006 to 2010 he was at Neuropharm Group plc as Chief Financial Officer. From 2011 to 2018 he was at hVIVO plc (formerly Retroscreen Virology Group plc) as Chief Financial & Business Officer. Graham has a first-class BSc in Economics and Maths from the University of Bristol.

John joined OrganOx as a Non-Executive Director in January 2019 and has a focus on service sector; industrial and technology companies. He is also currently a Non-Executive Director of Playtech PLC. He is formally a Panel Member at the Competition and Markets Authority, Chairman of Wavex Ltd, a City-based IT services company, and Non-Executive Director of Hogg Robinson Group PLC.

Earlier in his career, John was a Managing Director at both Morgan Stanley and Deutsche Bank, and has over 20 years experience in international corporate finance across a wide variety of industry sectors and geographies, with specific public and private market advisory experience in: mergers & acquisitions; market reviews and strategy development; IPOs and capital markets; hostile shareholder and defence considerations; and public market communications.

John holds B.A., M.A. and M.Eng. degrees from the University of Cambridge, and an MBA from the Harvard Business School.

John is passionate about education, particularly the promotion of STEM. He has advised the Department for Education on academy governance, he is a Trustee at Big Education Trust, a multi-academy trust in East London and was Trustee and Finance Committee Chair of the Royal Institution of Great Britain.

Tim joined the OrganOx board as a Non-Executive Director in January 2020 following the investment by BGF. Tim has been active in the venture capital and start-up ecosystem for over 20 years, initially as an entrepreneur and then as an investor with SoftBank, NEC and DFJ ePlanet Capital. He has been a party to more than 120 investments across a broad range of sectors, stages and geographies.

At BGF Tim is responsible for identifying and executing investments, with a particular focus on tech-orientated propositions.

Outside of work Tim spends as much of his time as possible on horseback and, in the interest of combining work with pleasure, keeps a horse specifically for long conference calls. Tim has a science background and began his career in BT’s research labs developing materials for optical switching and amplification. He has an MBA from London Business School.

Matthew joined the OrganOx board as a Non-Executive Director in 2009, when the company spun-out from the University of Oxford. Matthew has over twenty years of experience as a venture investor, focusing on highly disruptive healthcare, medtech and life science opportunities. In addition to OrganOx, he sits on other boards including Caristo Diagnostics, OxSonics, Momentum BioSciences, BioFidelity and Lightcast Discovery.

Matthew has a D.Phil (Biochemistry) from Oxford. After a brief research career, he began investing in early stage companies through Oxford Technology Management, before co-founding Longwall Venture Partners. Longwall has raised three funds over the last decade, and invests in early stage, UK-based science, engineering and healthcare businesses

Adam is a Non-Executive Director on behalf of the University of Oxford. Adam has over 15 years’ experience in the venture capital sector. He joined Oxford University Innovation in October 2016 as Head of New Venture Support & Funding. Prior to OUI Adam was a Partner in the cleantech focused venture capital fund manager 350 Investment Partners. He formerly worked with the Carbon Trust, 3i and Shell Exploration. He has an MA in Natural Sciences and a Postgraduate diploma in Computer Science from Cambridge University.

George joined the OrganOx board in 2009, when the company spun-out from the University of Oxford. George is Founder of Oxford Investment Consultants and a Partner and co-Founder of Sloane Robinson LLP, an investment management business which invests in listed equities globally, with a particular focus on Asian and Emerging Markets.

George is an active investor in early stage technology and biotech companies with a particular focus on Oxford spinouts, and is a founding Partner of Technikos, a private equity partnership which invests in spinout companies from the Oxford Institute of Biomedical Engineering.

George is an honorary fellow of Keble College, Oxford where he graduated with a BA in Engineering Science, and is a former-member of Oxford University Endowment Management’s Investment Committee.